Author

Arnon Aharon

Observed name: A. Aharon

Observed institution: BioLineRx Ltd. (Israel)

OpenAlex ID: A5087135381

A blocking monoclonal antibody to CCL24 alleviates liver fibrosis and inflammation in experimental models of liver damage

2020 · Michal Segal-Salto, Neta Barashi, et al. · JHEP Reports · 55

PDF

Single Dose of the CXCR4 Antagonist BL-8040 Induces Rapid Mobilization for the Collection of Human CD34+ Cells in Healthy Volunteers

2017 · Michal Abraham, Yaron Pereg, et al. · Clinical Cancer Research · 52

BL‐8040 CXCR4 antagonist is safe and demonstrates antileukemic activity in combination with cytarabine for the treatment of relapsed/refractory acute myelogenous leukemia: An open‐label safety and efficacy phase 2a study

2020 · Gautam Borthakur, Yishai Ofran, et al. · Cancer · 43

PDF

A Novel Proliposomal Ropivacaine Oil: Pharmacokinetic–Pharmacodynamic Studies After Subcutaneous Administration in Pigs

2016 · Elyad M. Davidson, Simon Haroutounian, et al. · Anesthesia & Analgesia · 24

Proliposomal Ropivacaine Oil: Pharmacokinetic and Pharmacodynamic Data After Subcutaneous Administration in Volunteers

2016 · Yehuda Ginosar, Simon Haroutounian, et al. · Anesthesia & Analgesia · 20

The Peptidic CXCR4 Antagonist, BL-8040, Significantly Reduces Bone Marrow Immature Leukemia Progenitors By Inducing Differentiation, Apoptosis and Mobilization: Results of the Dose Escalation Clinical Trial in Acute Myeloid Leukemia

2015 · Gautam Borthakur, Yishai Ofran, et al. · Blood · 18

Real-world experience with the IUB Ballerine MIDI copper IUD: an observational study in the French-speaking region of Switzerland

2019 · Michal Yaron, Manuela Viviano, et al. · The European Journal of Contraception & Reproductive Health Care · 14

PDF

BL-8040, a Peptidic CXCR4 Antagonist, Induces Leukemia Cell Death and Specific Leukemia Cell Mobilization in Relapsed/Refractory Acute Myeloid Leukemia Patients in an Ongoing Phase IIa Clinical Trial

2014 · Gautam Borthakur, Arnon Nagler, et al. · Blood · 14

Prolonged Analgesic Effect of PRF-108 and PRF-110 on Post-operative Pain in Pigs

2016 · David Castel, Michael Naveh, et al. · Pain and Therapy · 10

PDF

Real-world experience with the IUB Ballerine MIDI copper IUD: an observational, single-centre study in Israel

2019 · Ilan Baram, Arnon Aharon, et al. · The European Journal of Contraception & Reproductive Health Care · 8

The Selective Anti Leukemic Effect of BL-8040, a Peptidic CXCR4 Antagonist, Is Mediated By Induction of Leukemic Blast Mobilization, Differentiation and Apoptosis: Results of Correlative Studies from a Ph2a Trial in Acute Myeloid Leukemia

2016 · Gautam Borthakur, Martin S. Tallman, et al. · Blood · 5

Effect of BL-8040, high-affinity CXCR4 antagonist, on T-cell infiltration, tumor growth, and synergy with immunomodulatory agents.

2017 · Michal Abraham, Inbal Mishalian, et al. · Journal of Clinical Oncology · 3

CCL24 modulates fibrosis development in primary sclerosing cholangitis: correlation of human serum CCL24 levels with fibrosis markers and data from the Mdr2–/– mouse model.

2020 · Neta Barashi, Michal Segal, et al. · Journal of Hepatology · 2

PDF

Final Phase IIa Study Results Evaluating the CXCR4 Antagonist BL-8040 in Combination with Cytarabine (Ara-C) for the Treatment of Relapsed/Refractory AML Patients

2016 · Gautam Borthakur, Martin Tallman, et al. · Clinical Lymphoma Myeloma & Leukemia · 1

Targeted long-acting cisplatin–SRGel for enhanced chemoradiation in head and neck cancer: Preclinical pharmacokinetics, safety, and efficacy.

2026 · Peter Siman, Arnon Aharon, et al. · Journal of Clinical Oncology

Preliminary efficacy and safety of intratumoral long-acting cisplatin-SRGel (TumoCure) in refractory locally advanced head and neck squamous cell carcinoma: Phase Ib CLPR-001.

2026 · Arnon Aharon, Christine Warwar Damouny, et al. · Journal of Clinical Oncology

Abstract A056: Targeting the Protein Regulator of Cytokinesis 1 (PRC1) Pathway in Pancreatic Cancer

2025 · Amnon Peled, Michal Abraham, et al. · Cancer Research

Abstract 6874: Bkt300, a novel small molecule targeting the protein regulator of cytokinesis 1 pathway in hepatocellular carcinoma

2025 · Amnon Peled, Lika Gamaev, et al. · Cancer Research

BKT300: A Novel Anti-Leukemic Small Molecule Targeting the Protein Regulator of Cytokinesis 1 (PRC1) Pathway

2025 · Amnon Peled, Michal Abraham, et al. · Research Square

Abstract 674: Novel anti-cancer small molecule targeting the protein regulator of cytokinesis pathway

2024 · Amnon Peled, Michal Abraham, et al. · Cancer Research

Table S3 from Single Dose of the CXCR4 Antagonist BL-8040 Induces Rapid Mobilization for the Collection of Human CD34+ Cells in Healthy Volunteers